Literature DB >> 28846034

Advances in the use of Xenopus for successful drug screening.

Lorena A Maia1, Ian Velloso1, Jose G Abreu1.   

Abstract

INTRODUCTION: Understanding embryogenesis currently relies largely on the control of gene expression via several signaling pathways. Many of the embryonic signaling pathways guiding embryological events are implicated in diseases that lack effective cure or treatment. Because of the large number and size of the eggs, the rapid development of the embryos and the fact they are amenable to pharmacological, surgical and genetic techniques, Xenopus laevis has been successfully used in searching for compounds that target embryonic signaling pathways. Areas covered: Here, the authors address the use of amphibian eggs/embryos in successful chemical screenings; egg extracts as well as embryo phenotypes have been assayed to reveal drug toxicology effects and novel compounds acting in the Wnt/β-catenin signaling pathway. They do not discuss the use of Xenopus oocyte two-electrode voltage clamps or genome editing tools as approaches for drug discovery because they have been discussed elsewhere. Expert opinion: While high-throughput screening is commonly performed in egg extracts, the embryo axes perturbation system is more suited to the refinement and/or the validation of drug discovery targeting embryonic signaling (particularly the Wnt/β-catenin pathway). In addition, Xenopus has also been used in FETAX (frog embryo teratogenesis assay: Xenopus) to address chemical toxic/teratogenic effects. However, further studies are necessary.

Entities:  

Keywords:  Amphibian embryo; FETAX; Wnt; chemical screening; embryonic axis formation; flavonoids; natural compounds; translational developmental biology

Mesh:

Year:  2017        PMID: 28846034     DOI: 10.1080/17460441.2017.1367281

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  7 in total

1.  An in vivo brain-bacteria interface: the developing brain as a key regulator of innate immunity.

Authors:  Celia Herrera-Rincon; Jean-Francois Paré; Christopher J Martyniuk; Sophia K Jannetty; Christina Harrison; Alina Fischer; Alexandre Dinis; Vishal Keshari; Richard Novak; Michael Levin
Journal:  NPJ Regen Med       Date:  2020-02-04

2.  E-liquids and vanillin flavoring disrupts retinoic acid signaling and causes craniofacial defects in Xenopus embryos.

Authors:  Amanda J G Dickinson; Stephen D Turner; Stacey Wahl; Allyson E Kennedy; Brent H Wyatt; Deborah A Howton
Journal:  Dev Biol       Date:  2021-09-17       Impact factor: 3.582

3.  Degenerative Osteoarthropathy in Laboratory Housed Xenopus (Silurana) tropicalis.

Authors:  Mingyun Zhang; Sabrina S Wilson; Kerriann M Casey; Paisley E Thomson; Anne L Zlatow; Valerie S Langlois; Sherril L Green
Journal:  Comp Med       Date:  2021-11-18       Impact factor: 1.565

4.  Toward Decoding Bioelectric Events in Xenopus Embryogenesis: New Methodology for Tracking Interplay Between Calcium and Resting Potentials In Vivo.

Authors:  Patrick McMillen; Richard Novak; Michael Levin
Journal:  J Mol Biol       Date:  2019-11-09       Impact factor: 5.469

5.  A Label-free Multicolor Optical Surface Tomography (ALMOST) imaging method for nontransparent 3D samples.

Authors:  Axelle Kerstens; Nikky Corthout; Benjamin Pavie; Zengjin Huang; Frank Vernaillen; Greetje Vande Velde; Sebastian Munck
Journal:  BMC Biol       Date:  2019-01-07       Impact factor: 7.431

6.  An in vivo brain-bacteria interface: the developing brain as a key regulator of innate immunity.

Authors:  Celia Herrera-Rincon; Jean-Francois Paré; Christopher J Martyniuk; Sophia K Jannetty; Christina Harrison; Alina Fischer; Alexandre Dinis; Vishal Keshari; Richard Novak; Michael Levin
Journal:  NPJ Regen Med       Date:  2020-02-04

Review 7.  Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer.

Authors:  Luiz F S Oliveira; Danilo Predes; Helena L Borges; Jose G Abreu
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.